RPS6KB1 and neoplasm: Pharmacological inhibition of S6K1 using the selective inhibitor PF-4708671 not only attenuated gefitinib resistance in resistant models, while simultaneously enhancing anti-tumor efficacy through targeted pathway suppression, thereby establishing S6K1 as a master regulator of adaptive resistance.